Tilray | TRLY - Sales Revenues

Stock Price
10.70
Daily Change
-0.15 -1.38%
Monthly
-11.13%
Yearly
838.60%
Q1 Forecast
10.37

Tilray reported $217.51M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Acasti Pharma USD -4.76M 4.76M Dec/2024
Akebia Therapeutics USD 57.34M 10.84M Mar/2025
Alaunos Therapeutics USD 2K 2K Mar/2025
Aurora Cannabis CAD 90.37M 7.65M Sep/2025
Avita Medical AUD 18.42M 14K Jun/2025
Canopy Growth CAD 66.68M 5.45M Sep/2025
Cronos Group USD 36.34M 2.88M Sep/2025
Dianthus Therapeutics USD 396K 203K Sep/2025
Divis Laboratories Ltd INR 26.04B 1.11B Dec/2025
Ionis Pharmaceuticals USD 203M 46M Dec/2025
IQVIA Holdings USD 4.36B 260M Dec/2025
Knight Therapeutics CAD 92.26M 3.31M Sep/2024
Moderna USD 678M 342M Dec/2025
Organigram Holdings CAD 80.06M 9.27M Sep/2025
Organon & Co USD 1.51B 90M Dec/2025
Revvity USD 772.06M 73.06M Dec/2025
Tectonic Therapeutic USD 0 0 Dec/2024
Tilray USD 217.51M 74.75M Dec/2025
Viatris USD 3.76B 190M Sep/2025
Xeris Pharmaceuticals USD 74.38M 2.84M Sep/2025